Previous Close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.6000 |
Strike | 2.50 |
Expire Date | 2024-10-18 |
Day's Range | 0.1000 - 0.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 15 |
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS). Once issued, this patent is expec
LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cov
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Imagine if you held MediciNova, Inc...